

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HS  
W/M/11  
JPP

In re application of:

NI *et al.*

Appl. No. 09/448,868

Filed: November 24, 1999

For: **Death Domain Containing  
Receptor-4 Antibodies**



Art Unit: 1646

Examiner: To Be Assigned

Atty. Docket: 1488.1300004/EKS/EJH

**First Supplemental Information Disclosure Statement**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on March 7, 2000 in connection with the above-captioned application.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications which are directed to related subject matter:

U.S. Patent Application 08/799,180, filed February 12, 1997; and

U.S. Patent Application 08/975,985, filed February 12, 1997.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Thus, no statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Elizabeth J. Haanes, Ph.D.  
Agent for Applicants  
Registration No. 42,613

Date: April 12, 2000

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

## STERNE, KESSLER, GOLDSTEIN &amp; FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600  
WASHINGTON, D.C. 20005-3934

RECEIVED

APR 13 2000

1646

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

TECH CENTER 1604/2900

ROBERT GREENE STERNE  
 EDWARD J. KESSLER  
 JORGE A. GOLDSTEIN  
 SAMUEL L. FOX  
 DAVID K.S. CORNWELL  
 ROBERT W. EDMOND  
 TRACY-GENE G. DURKIN  
 MICHELE A. CIMBALA  
 MICHAEL B. RAY  
 ROBERT E. SOKOHL  
 ERIC K. STEFFE  
 MICHAEL O. LEE

STEVEN R. LUDWIG  
 JOHN M. COVERT\*  
 LINDA E. ALCORN  
 RAZ E. FLESHNER  
 ROBERT C. MILLONIG  
 MICHAEL V. MESSINGER  
 JUDITH U. KIM  
 TIMOTHY J. SHEA, JR.  
 DONALD R. MCPHAIL  
 PATRICK E. GARRETT  
 STEPHEN G. WHITESIDE  
 JEFFREY T. HELVEY\*

HEIDI L. KRAUS  
 JEFFREY R. KURIN  
 RAYMOND MILLIEN  
 PATRICK D. O'BRIEN  
 LAWRENCE B. BUGAISKY  
 CRYSTAL D. SAYLES\*  
 EDWARD W. YEE  
 ALBERT L. FERRO\*  
 DONALD R. BANOWIT  
 PETER A. JACKMAN  
 MOLLY A. MCCALL

TERESA U. MEDLER  
 JEFFREY S. WEAVER  
 KRISTIN K. VIDOVICH  
 KENDRICK P. PATTERSON  
 DONALD J. FEATHERSTONE  
 GRANT E. REED  
 VINCENT L. CAPUANO  
 JOHN A. HARROUN\*  
 MATTHEW M. CATLETT\*  
 NATHAN K. KELLEY\*  
 ALBERT J. FASULO II \*

KAREN R. MARKOWICZ\*\*  
 SUZANNE E. ZISKA\*\*  
 BRIAN J. DEL BUONO\*\*  
 ANDREA J. KAMAGE\*\*  
 NANCY J. LEITH\*\*  
 TARJA H. NAUKKARINEN\*\*

\*BAR OTHER THAN D.C.  
 \*\*REGISTERED PATENT AGENTS

April 12, 2000

WRITER'S DIRECT NUMBER:

(202) 218-7834

INTERNET ADDRESS:  
 BHAANES@SKGF.COM

Assistant Commissioner for Patents  
 Washington, D.C. 20231



Re: U.S. Utility Patent Application  
 Appl. No. 09/448,868; Filed: November 24, 1999  
 For: **Death Domain Containing Receptor-4 Antibodies**  
 Inventors: Ni *et al.*  
 Our Ref: 1488.1300004/EKS/EJH

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. Form PTO-1449 (1 sheet citing 2 documents);
3. Two (2) cited documents (AO1 and AP1); and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Assistant Commissioner for Patents  
April 12, 2000  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.  
Agent for Applicants  
Registration No. 42,613

EKS/EJH/cmg  
Enclosures

P:\USERS\BHAANES\Work Products\1488\130\1300004\1stSuppIDS

